

Operational Update and Appendix 4C

Quarterly Cashflow Report

Xenitra Limited (ASX:XEN) (Xenitra or the Company) is pleased to provide its operational update and Appendix 4C quarterly cashflow report for the three months ended 30 June 2026 (Q4 FY26).

Highlights

- **Positive operating cash flow** of A\$0.8 million, representing an A\$2.13 million improvement from the A\$1.33 million operating cash outflow in Q3 FY26 and an A\$2.46 million improvement from the A\$1.66 million outflow in Q4 FY25
- **Improved cash conversion.** Customer receipts were A\$5.33 million, while product manufacturing and operating payments reduced to A\$3.75 million, 56% below Q3 FY26 and 77% below the prior corresponding period. Demonstrating the new leaner, higher margin business model taking shape.
- **Higher-quality sales mix.** Preliminary unaudited management accounts recorded Q4 sales of circa A\$5 million and gross profit margin of approximately 16%, compared with Q3 gross profit <5%. This was driven by a shift to higher margin sales channels, primarily the OPAL sales ecosystem.
- **Strong closing liquidity.** Xenitra ended the quarter with A\$3.79 million cash, up from A\$1.83 million at 31 March 2026, following positive operating cash flow and net financing inflows of A\$1.26 million.
- **OPAL launch validated.** Product sales through the OPAL RWA-tokenised sales ecosystem exceeded A\$1.5 million in the first quarter of sales for the EZZ range of products exclusively distributed.
- **OPAL ecosystem growing strongly** with Biomiq skincare joining the ecosystem as the second leading Australian brand and more than 500 distribution partners now onboarded
- **OTC platform established** through the acquisition and operationalisation of Hong Kong Fukang Trading Co., including its Hong Kong pharmaceutical wholesale licence, ecommerce shopfront, logistics infrastructure, trademark and inventory
- **OTC commercial execution** accelerated after quarter end with the announcement of a three-year procurement agreement with Kangsheng targeting a minimum A\$12 million in sales
- **Leaner operating platform.** The restructuring programme continued to remove non-core activities, reduce fixed infrastructure and concentrate resources on the higher-margin OTC and OPAL growth engines.

Non-Executive Chairman, Dr Anthony Noble, commented: “Q4 provides the clearest evidence to date of Xenitra’s turnaround. Customer receipts were lower as the Company reduced its exposure to low-margin, working-capital-intensive trading, but product and operating payments reduced much more substantially. The result was an A\$2.13 million quarter-on-quarter improvement in operating cash flow and the second positive operating cash-flow quarter of FY26.

The strategic shift is now visible in both the cash flow and the gross-margin profile of the business. Nutritionals remains an important scale and distribution pillar, but growth is increasingly being directed to OTC medicines and OPAL-tokenised sales, where the Company believes the margin and cash-return characteristics are materially stronger. The OPAL launch delivered rapid sales and distributor growth, while the Fukang acquisition created the platform for our OTC strategy to move into commercial execution.

Xenitra enters FY27 with a leaner structure, stronger liquidity and all three strategic pillars active. The focus is now disciplined execution, scaling the new growth engines and converting the strategic progress of FY26 into sustainable, profitable growth.”

Financial Update

Q4 FY26 marked a significant improvement in the quality of Xenitra’s cash generation. Customer receipts declined slightly as the Company deliberately moderated lower-margin, working-capital-intensive nutritionals activity and as the timing and mix of sales changed. Importantly, product manufacturing and operating payments declined at a substantially faster rate, producing positive operating cash flow.

Cash-flow metric (\$A'000)	Q4 FY26	Q3 FY26	Q4 FY25	Q4 commentary
Customer receipts	5,333	7,802	15,537	Down 32% QoQ; reflects lower legacy trading volume and sales timing.
Product manufacturing and operating payments	(3,746)	(8,491)	(16,333)	Down 56% QoQ and 77% PCP reflecting a shift to higher margin sales via the OPAL network.
Cash trading contribution*	1,587	(689)	(796)	A\$2.28m QoQ improvement before overheads.
Advertising, staff and administration payments	(817)	(634)	(895)	QoQ increase reflects growth-platform mobilisation and significant restructuring and legal costs associated with legacy business.
Net operating cash flow	800	(1,333)	(1,660)	A\$2.13m QoQ and A\$2.46m PCP improvement.
Closing cash balance	3,790	1,830	1,677	Up 107% QoQ; includes net financing inflows.

**Cash trading contribution is a non-IFRS management measure calculated as customer receipts less product manufacturing and operating payments. It is presented to illustrate the change in cash conversion and is not a substitute for statutory operating cash flow.*

Cash-flow turnaround

The most important Q4 movement was the improvement in cash generated from trading activity. Product manufacturing and operating payments represented approximately 70% of customer receipts in Q4, compared with 109% in Q3 FY26 and 105% in Q4 FY25. The resulting A\$1.59 million cash trading contribution was sufficient to fund staff, administration, marketing and finance payments and still produce A\$0.80 million of positive net operating cash flow.

Core cash expenditure across advertising, staff and administration was A\$0.82 million, approximately 9% below Q4 FY25. The increase from Q3 FY26 primarily reflected the mobilisation and scaling of the OPAL business unit, together with corporate, legal and year-end activities. The addition of the high margin OTC pharmaceutical business unit in FY27 will further accelerate this transition to profitable sales in the overall mix. The Company will continue to apply disciplined cost control as these growth platforms scale. The Company closed the quarter with A\$3.79 million in cash.



Gross Margin Analysis

Management-account metric	Q4 FY26	Q3 FY26	Movement
Sales (\$A'm)	4.872	8.343 (41.6%)	
Gross profit / (loss) (\$A'm)	0.792	(0.019) +0.811	
Gross margin	16.3%	(0.2%) +16.5%	

The P&L figures above are preliminary, unaudited management-account figures before completion of the FY26 audit and final year-end adjustments. They may change and should not be treated as audited financial results.

The Gross Margin Analysis illustrates the transition in revenue quality. While Q4 sales were lower than Q3, gross profit improved by approximately A\$0.81 million and gross margin increased materially. The positive operating cash-flow result demonstrates that the restructuring is already improving cash conversion while the new growth platforms are being established.

Operational Update

During Q4 FY26 Xenitra progressed from strategy formation and platform build-out to active execution across its three growth pillars. Nutritionals continued to provide scale and established market access, while OTC medicines and OPAL-tokenised sales moved from development into market and commercial execution. These two newer channels are central to the Company's objective of building a higher-margin, more capital-efficient sales mix.

Pillar 1: Nutritionals with disciplined scale and channel foundation

The Nutritionals business remains the Company's established revenue base and provides the supply-chain, customer, ecommerce and B2B infrastructure upon which the broader Xenitra platform has been built. During Q4 the Company continued to service nutritionals demand while applying greater discipline to sales selection, procurement commitments and working-capital returns.

Delivery during Q4 FY26

- The Danone product supply agreement with Rockcheck commenced on 1 May 2026 and targets 140 million RMB, approximately A\$30 million, in product sales over the period to 30 April 2027. The agreement includes an option for a further three-year extension subject to performance.
- The broader authorised-supplier framework established Xenitra's Australian trading subsidiary as an approved supplier to the Rockcheck Group, creating the potential to add additional product categories and brand partners to the B2B relationship.
- The Company moderated sales where margin, payment terms or inventory requirements did not meet revised return thresholds. This contributed to lower receipts, but the reduction in product payments was substantially greater and materially improved operating cash flow.
- The established nutritionals distribution network continued to provide customer access, logistics capability and commercial infrastructure that can also support OTC and exclusive-brand opportunities.

Strategic role in FY27

Nutritionals will continue to be managed as a disciplined scale business, with priority given to larger B2B customers, attractive payment terms and transactions that make a positive contribution after working-capital costs. The objective is not growth in low-margin volume for its own sake, but a stable, cash-generative base that supports the expansion of the higher-margin pillars.

Pillar 2: OTC medicines – new high-margin growth engine

The OTC medicines strategy addresses a large and rapidly developing cross-border healthcare channel into Greater China. Xenitra's approach is to combine pharmaceutical licensing and compliant supply with its existing ecommerce, distribution and brand-acceleration capabilities. Q4 was the foundational execution quarter for this pillar with only minimal revenues recognised, but with significant investments made and foundations laid.



Fukang acquisition completed and platform operationalised

On 15 April 2026 Xenitra acquired 100% of Hong Kong Fukang Trading Co., Limited and the assets required to commence and expand the OTC medicines business for total consideration of approximately A\$97,000. The acquisition included Hong Kong pharmaceutical wholesale licence PW-2024-00189, the licensed premises, an established JD.com shopfront deposit, a Class 35 trademark, warehouse and logistics arrangements, inventory and operating infrastructure. The Fukang platform provides the Company with a compliant base for cross-border online OTC sales into mainland China and for pharmaceutical wholesale activities from Hong Kong.

During the quarter Xenitra integrated the acquired assets, progressed store and supply-chain operations, strengthened the specialist operating team and advanced discussions with international and domestic OTC suppliers and channel partners.

The OTC model is designed to generate materially higher gross margins than the legacy nutritionals trading business through specialised products, regulated market access, channel expertise and value-added sales and marketing execution.

Post-quarter commercial milestone: A\$12 million Kangsheng agreement

After quarter end, Xenitra announced a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading Limited. The agreement is expected to deliver a minimum A\$12 million in sales to Xenitra over three years through individual purchase orders fulfilled by Fukang, with initial commercial orders expected following completion of operational onboarding in Q1 FY27.

The Kangsheng agreement is the first major commercial agreement for the OTC division and moves the pillar from regulatory preparation and platform establishment into commercial execution. Kangsheng's ecommerce and retail-pharmacy distribution capabilities provide a route for international OTC and healthcare brands to access a broad customer network in China.

The Company's next priorities are to complete onboarding, commence initial orders, expand the approved product catalogue, build brand and master-distributor partnerships, and progressively develop both ecommerce and B2B or hospital-linked channels. OTC is expected to become a significant contributor to Xenitra's revenue mix as the platform scales, although the timing and value of individual orders will depend on customer demand, product availability and regulatory requirements.

Pillar 3: OPAL RWA-tokenised sales – launched and commercially validated

OPAL is Xenitra's blockchain-enabled sales, authentication, loyalty and rewards ecosystem. It links OPAL tokens to purchases of real consumer products distributed by Xenitra and uses the existing ecommerce and distributor network to create a differentiated, closed commercial ecosystem. Q4 delivered the technology launch, first product sales and rapid validation of the model.

Launch and sales acceleration

On 7 April 2026 Xenitra launched the OPAL Token and Xen Shop after more than six months of technology development. The platform operates on BNB Chain and links product purchases to authentication, token allocation, rewards and loyalty functionality.

EZZ Life Science products became the first range integrated into OPAL under Xenitra's previously announced four-year global distribution partnership.

Sales exceeded A\$100,000 in the first week, with more than 20 distributors onboarded. By the end of the first month, sales exceeded A\$500,000 and more than 130 distributors had joined the ecosystem. Within seven weeks, cumulative product sales exceeded A\$1.1 million and more than 400 distribution partners had been onboarded, demonstrating acceleration in both product uptake and network development. By the end of the quarter, sales have topped \$1.5m AUD with more than 500 distribution partners now onboarded.

The network created during the first launch can be reused for subsequent products and brands, reducing the time and cost required to establish each new commercial launch.



Commercial model and margin transformation

OPAL is designed to improve willingness to pay, repeat purchase and customer engagement through authenticity assurance, rewards and membership utility. A portion of the margin generated from qualifying product sales is allocated to the OPAL Token Reserve, which supports rewards and benefits within the ecosystem. This creates a self-reinforcing commercial model anchored to real product sales rather than speculative token activity.

Products are procured under exclusive or strategic distribution arrangements and sold through the tokenised channel at margins that management expects to be materially higher than the legacy nutritionals business. The reserve and rewards mechanism is funded from sales economics, allowing the ecosystem to expand across multiple brands without relying solely on traditional advertising expenditure or large increases in corporate overhead.

Biomiq becomes the second OPAL brand

In June Xenitra entered a four-year agreement appointing the Company as exclusive distributor of Biomiq Skincare in Greater China, with minimum product offtake of A\$5 million required to retain exclusivity. Biomiq is scheduled to become the second major brand launched through OPAL, with a target launch in August 2026. Integration of a second brand is an important test of the platform's ability to repeat and scale the launch model beyond EZZ.

The Biomiq range comprises more than 20 Australian-made skincare products across acne, minor skin conditions and anti-ageing applications, providing a differentiated product portfolio suited to ecommerce, social commerce and distributor-led selling.

The Company continues to assess additional brands and product categories that can benefit from exclusive distribution, authentication, loyalty and tokenised rewards.

Corporate restructuring and a leaner operating model

The improvement in Q4 operating cash flow reflects the restructuring programme undertaken across FY26. Xenitra has progressively simplified the corporate structure, removed fixed infrastructure, concentrated resources closer to its core China operations and redirected management attention from low-return activities to the three strategic growth pillars.

The programme was designed to deliver approximately A\$1 million in annualised savings compared with the former corporate structure. Australian headcount and duplicated functions were reduced where activities could be performed more efficiently within the operating markets. Australian office and rental costs were removed and corporate functions were consolidated, creating a more flexible operating platform. The Company continued to progress the exit, wind-up or resolution of non-core and non-trading joint-venture interests. These activities are intended to reduce complexity, governance burden and partner risk and are ongoing, through legal avenues.

Sales and procurement disciplines were tightened so that legacy nutritionals transactions are assessed on contribution, payment terms and working-capital efficiency rather than revenue volume alone. Resources were redirected to specialist OTC, ecommerce, pharmaceutical and tokenisation capabilities that can support higher-margin growth without recreating the historic fixed-cost structure.

The quarter-on-quarter movement from an A\$1.33 million operating cash outflow to A\$0.80 million positive operating cash flow is a tangible measure of the restructuring's impact. The Company will continue to review all costs and non-core activities while maintaining the resources required to execute the OTC and OPAL growth programmes.

Priorities for Q1 FY27

- Complete commercial onboarding and commence initial OTC orders under the Kangsheng agreement.
- Launch Biomiq Skincare in Greater China through the OPAL ecosystem and existing ecommerce and distributor channels and expand the number of new brands launching into the ecosystem.
- Continue scaling OPAL product sales, distributor participation and the pipeline of additional brand partners.
- Execute the Rockcheck nutritionals agreement with disciplined margin and working-capital management.
- Progress the simplification of non-core entities and maintain stringent control over fixed corporate expenditure.
- Preserve liquidity while directing investment to activities with the clearest path to sustainable gross profit and positive operating cash flow.

The Company believes the combination of a leaner cost base, an established nutritionals platform and two new higher-margin growth engines provides a substantially stronger foundation for FY27.



This announcement has been authorised for release by the Board of Xenitra Limited.

-Ends-

Investor Relations

Harry Spillane | Investor Relations

harry@blackwateradvisors.com.au

+61 447 757 550

About Xenitra Limited

Xenitra Limited (ASX:XEN) is a cross-border consumer goods distribution and brand-acceleration company connecting international FMCG, nutritionals, over-the-counter medicines and personal-care brands with consumers in Greater China. The Company operates a channel-optimised sales ecosystem spanning B2B trading, ecommerce, retail distribution and blockchain-enabled tokenised sales through the OPAL platform.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's plans, strategies, objectives, anticipated sales, margins, product launches, commercial agreements, operating costs and market opportunities. Forward-looking statements are not guarantees or predictions of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company's control. Actual outcomes may differ materially from those expressed or implied. Readers should not place undue reliance on forward-looking statements. Except as required by law or applicable regulation, the Company undertakes no obligation to update or revise these statements. Past performance is not a guide to future performance



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Xenitra Limited

ABN

79 150 110 017

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	5,333	22,771
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(3,746)	(20,496)
(c) advertising and marketing	(44)	(194)
(d) staff costs	(353)	(1,303)
(e) administration and corporate costs	(420)	(1,484)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	1	1
1.5 Interest and other costs of finance paid	(9)	(31)
1.6 Income taxes refunded	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other - mainly from GST refunds	37	239
1.9 Net cash from / (used in) operating activities	800	(497)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	(99)	(139)
(b) businesses	-	-
(c) property, plant and equipment	(5)	(8)
(d) investments	-	-
(e) intellectual property	(79)	(79)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Reclassification of Term Deposit)	46	115
2.6	Net cash from / (used in) investing activities	(136)	(110)

	3. Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,250	2,789
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(93)	(201)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(7)	(7)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	110	110
3.10	Net cash from / (used in) financing activities	1,260	2,690

	4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,830	1,677
4.2	Net cash from / (used in) operating activities (item 1.9 above)	800	(497)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(136)	(110)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,260	2,690

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	37	30
4.6	Cash and cash equivalents at end of period	3,790	3,790

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	3,790	1,830
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	3,790	1,830

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	122
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
The balance in 6.1 consists of \$75,333 directors' fees, \$6,875 senior leader's fee, and \$39,410 legal fees paid to related parties of Xenitra Ltd, and their associates.		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,000	1,000
7.2	Credit standby arrangements	-	-
7.3	Other	-	-
7.4	Total financing facilities	1,000	1,000
7.5	Unused financing facilities available at quarter end		-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	7.1 Loan facilities – loan from Zoomcoo (also shareholder) for working capital.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	800
8.2	Cash and cash equivalents at quarter end (item 4.6)	3,790
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	3,790
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.